Bosutinib versus imatinib for newly diagnosed chronic phase CML: BFOREfinal 5-year results

FORTE trial: Impact of minimal residual disease on multiple myeloma patients

Clinical implications of MRD detection in infants with KMT2A-rearranged ALL Treated on the Interfant-06 protocol

PARP inhibitors in prostate cancer: A promise delivered

Clinical genomic testing in prostate cancer

PARP inhibitors for prostate cancer - Nurse's view

Using circulating tumour DNA dynamics to predict outcomes in advanced cancers

OncoAlert and ecancer weekly roundup for November 8 - 14, 2020

OncoAlert and ecancer weekly roundup for November 2 - 7, 2020

Evolving concepts in the diagnosis and staging of multiple myeloma

SAFIR 02: Durvalumab compared to maintenance chemotherapy for metastatic non-small cell lung cancer

Managing multiple myeloma during the COVID-19 pandemic in Brazil